VC005 clinical trials
Also written VC005.
How each study uses VC005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VC005 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
21 studies that test it; most in 2026 (9)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test VC005, phase 3 first.
- Aug 2027Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisPhase 3 · Jiangsu vcare pharmaceutical technology co., LTD
- Aug 2027Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.Phase 3 · Jiangsu vcare pharmaceutical technology co., LTD
- Nov 2026Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult SubjectsPhase 1 · Jiangsu vcare pharmaceutical technology co., LTD
- Feb 2027A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic DermatitisPhase 2 · Jiangsu vcare pharmaceutical technology co., LTD
- May 2027A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental VitiligoPhase 1/2 · Jiangsu vcare pharmaceutical technology co., LTD
- Aug 2027Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental VitiligoPhase 2 · Jiangsu vcare pharmaceutical technology co., LTD
Studies
Open first, then newest update. How each study uses VC005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia AreataRecruitingPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07762443Written as VC005 tablets
- A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental VitiligoNot yet recruitingPhase 1/2Jiangsu vcare pharmaceutical technology co., LTDNCT07828639Written as VC005 tablets
- Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult SubjectsNot yet recruitingPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07796191Written as VC005 and verapamil
- Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia AreataRecruitingPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT07749716Written as Drug: VC005 tablets
- Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisRecruitingPhase 3Jiangsu vcare pharmaceutical technology co., LTDNCT06723080Written as VC005 low dose group
- Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic DermatitisRecruitingPhase 3Jiangsu vcare pharmaceutical technology co., LTDNCT07592585Written as VC005
- A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic DermatitisRecruitingPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT07598383Written as VC005 group
- Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.RecruitingPhase 3Jiangsu vcare pharmaceutical technology co., LTDNCT07172360Written as VC005 tablets
- Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental VitiligoRecruitingPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT07172347Written as VC005 tablets
- Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07551557Written as VC005 Tablets
- Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal FunctionCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07551570Written as VC005 Tablets
- A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.CompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07533851Written as VC005 Tablets
- Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic DermatitisCompletedPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT06891040Written as VC005 groups
- Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic DermatitisCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT07329101Written as VC005
- The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male VolunteersCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT06974292Written as [14C]VC005
- Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic DermatitisCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT06009094Written as VC005
- Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisCompletedPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT05997927Written as VC005 tablets
- Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.CompletedPhase 2Jiangsu vcare pharmaceutical technology co., LTDNCT05814939Written as VC005 tablets
- A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.CompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT05874622Written as VC005 tablets
- Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy SubjectsCompletedPhase 1Jiangsu vcare pharmaceutical technology co., LTDNCT05354752Written as VC005 tablets
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
- A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia AreataOct 20, 2026NCT07762443